Clinical Trial Update: A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating THR-317 for Macular Telangiectasia Type 1 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Juxtafoveal Retinal Telangiectasia
• Macular Telangiectasia Type 1
• Retinal Telangiectasis

Drugs mentioned

• THR-317

Snippet

Sponsor: ThromboGenics | Conditions: Retinal Telangiectasis, Idiopathic Juxtafoveal Retinal Telangiectasia | Phase 2 | Status: COMPLETED